Advertisement

Topics

Two Investigational Drugs in Patients With Mixed Hyperlipidemia

2014-07-24 14:33:09 | BioPortfolio

Summary

The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

Description

The duration of treatment is 18 weeks.

Study Design

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment

Conditions

Hypercholesterolemia

Intervention

MK0653, ezetimibe, Comparator: fenofibrate monotherapy

Status

Completed

Source

Merck

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:33:09-0400

Clinical Trials [595 Associated Clinical Trials listed on BioPortfolio]

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia

A study to evaluate the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of the addition of ezetimibe to rosuvastatin compared with doubling dose of rosuvastatin in patients t...

A Study to Evaluate the Effects of MK0653 on the Postprandial (Following a Meal) Lipoprotein Response in Patients With Primary Hypercholesterolemia (High Cholesterol)

A study to evaluate the cholesterol-lowering effects of MK0653 in patients with primary hypercholesterolemia (high cholesterol) after eating a meal that is high in cholesterol.

MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)

This study will compare the lipid-altering efficacy and safety of switching to co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or rosuvastatin in high ca...

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia

To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.

Co-Administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease

The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current appro...

PubMed Articles [450 Associated PubMed Articles listed on BioPortfolio]

Effects of short term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.

The influence of short term add-on ezetimibe to simvastatin treatment on expression of adipokines and inflammatory markers was investigated in diabetic and non-diabetic patients with hypercholesterole...

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk...

Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia.

-Introduction: Cholesterol lowering treatment is mainly based on statins eventually associated to adjunctive drugs of different class such as ezetimibe. In the present review, we analysed the pharmaco...

Tendon Pathology in Hypercholesterolemia and Familial Hypercholesterolemia.

Hypercholesterolemia (HC), or high cholesterol, is usually caused by diet, other health conditions, or inherited diseases, such as familial hypercholesterolemia (FHC). Studies have shown patients with...

A Comparator-Hypothesis Account of Biased Contingency Detection.

Our ability to detect statistical dependencies between different events in the environment is strongly biased by the number of coincidences between them. Even when there is no true covariation between...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.

An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.

Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)

An allylamine derivative that binds BILE ACIDS in the intestine and is used as an ANTICHOLESTEREMIC AGENT in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

More From BioPortfolio on "Two Investigational Drugs in Patients With Mixed Hyperlipidemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cholesterol
Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...


Searches Linking to this Trial